These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10740646)

  • 1. [Two cases of acute myelogenous leukemia complicated with fatal gastrointestinal tract bleeding after treatment with idarubicin and cytarabine].
    Nagashima T; Izumi T; Muroi K; Miyasato A; Uchida M; Imagawa S; Komatsu N; Yoshida M; Hatake K; Miura Y; Ozawa K
    Gan To Kagaku Ryoho; 2000 Mar; 27(3):487-90. PubMed ID: 10740646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
    Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Alymara V; Tzouvara E; Vartholomatos G; Chaidos A; Tsiara S; Bourantas KL
    J Exp Clin Cancer Res; 2004 Sep; 23(3):447-54. PubMed ID: 15595635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute myelogenous leukemia associated with severe esophageal stricture after chemotherapy].
    Yata K; Yamada O; Iwato K; Kyo T; Otsuki T; Nakanishi H; Suetsugu Y; Mikami M; Wada H; Yawata Y; Sugihara T
    Rinsho Ketsueki; 2002 Jan; 43(1):41-3. PubMed ID: 11868364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
    Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
    Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.
    Weiss MA; Aliff TB; Tallman MS; Frankel SR; Kalaycio ME; Maslak PG; Jurcic JG; Scheinberg DA; Roma TE
    Cancer; 2002 Aug; 95(3):581-7. PubMed ID: 12209751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acute myelogenous leukemia complicated with severe tumor lysis syndrome after a single day of idarubicin/cytarabine chemotherapy].
    Kikuchi T; Miyata A; Fujii S; Kikuchi T
    Rinsho Ketsueki; 2003 Nov; 44(11):1113-6. PubMed ID: 14689878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoprotection in acute myelogenous leukemia (AML) therapy.
    Grosso D; Filicko J; Garcia-Manero G; Beardell F; Brunner J; Cohn J; Ferbér A; Martinez J; Mookerjee B; Rose L; Tice D; Wagner JL; Capizzi R; Flomenberg N
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):67-73. PubMed ID: 15726527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
    Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
    Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
    Pigneux A; Perreau V; Jourdan E; Vey N; Dastugue N; Huguet F; Sotto JJ; Salmi LR; Ifrah N; Reiffers J
    Haematologica; 2007 Oct; 92(10):1327-34. PubMed ID: 18024370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E
    Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside.
    Hogan WJ; Letendre L; Litzow MR; Tefferi A; Hoagland HC; Pruthi RK; Kaufmann SH
    Mayo Clin Proc; 2002 Aug; 77(8):760-2. PubMed ID: 12173711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study.
    Kim H; Park JH; Lee JH; Lee JH; Joo YD; Lee WS; Bae SH; Mo Ryoo H; Lee KH;
    Am J Hematol; 2009 Mar; 84(3):161-6. PubMed ID: 19195034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle.
    Ruutu T; Koivunen E; Nousiainen T; Pelliniemi TT; Almqvist A; Anttila P; Jantunen E; Koistinen P; Koponen A; Mikkola M; Oksanen K; Pulli T; Remes K; Sarkkinen R; Silvennoinen R; Timonen T; Vanhatalo S; Elonen E;
    Eur J Haematol; 2004 Jan; 72(1):38-44. PubMed ID: 14962261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients.
    Olivieri A; Capelli D; Troiani E; Poloni A; Montanari M; Offidani M; Discepoli G; Leoni P
    Exp Hematol; 2007 Jul; 35(7):1074-82. PubMed ID: 17588476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
    Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.